RBC Capital Maintains Outperform on Axsome Therapeutics, Raises Price Target to $304

Benzinga Newsdesk www.benzinga.com Positive 93.3%

Neg 0% Neu 0% Pos 93.3%

RBC Capital analyst Leonid Timashev maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform and raises the price target from $302 to $304.